71
Participants
Start Date
October 31, 2011
Primary Completion Date
September 30, 2013
Study Completion Date
September 30, 2013
Pomalidomide
Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
University of Arkansas for Medical Sciences, Myeloma Institute for Research and Therapy, Little Rock
Collaborators (1)
Celgene
INDUSTRY
University of Arkansas
OTHER